You just read:

AbbVie Receives CHMP Positive Opinion for HUMIRA® (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease

News provided by

AbbVie

04 Apr, 2016, 07:00 ET